NCT05221385: Gentulizumab in Patients With Advanced Solid Malignancies and Non-Hodgkin Lymphoma |
|
|
| Terminated | 1 | 58 | RoW | Gentulizumab | Changchun GeneScience Pharmaceutical Co., Ltd. | Solid Tumor, Non-Hodgkin Lymphoma | 05/23 | 10/23 | | |
NCT05263271: Gentulizumab in Relapsed/Refractory Acute Myelogenous Leukemia or Myelodysplastic Syndrome |
|
|
| Recruiting | 1 | 58 | RoW | Gentulizumab | GeneScience Pharmaceuticals Co., Ltd., Ruijin Hospital, Shanghai Tong Ren Hospital, First Affiliated Hospital of Zhejiang University | Acute Myelogenous Leukemia, Myelodysplastic Syndromes | 07/24 | 07/24 | | |
